Genocea Biosciences

Genocea releases positive results for genital herpes treatment GEN-003

Tuesday, April 5, 2016

Genocea Biosciences, a biopharmaceutical company developing T cell-directed vaccines and immunotherapies, has announced positive 12 month efficacy data from its phase II dose optimization trial evaluating GEN-003 for the treatment of genital herpes. GEN-003 demonstrated sustained and statistically significant reductions compared to baseline in the rate of viral shedding 12 months after dosing across multiple dose groups as well as sustained efficacy at multiple dose levels across secondary endpoints measuring the impact on clinical disease. GEN-003 was safe and well-tolerated by patients, with no serious adverse events related to the vaccine in the trial.

[Read More]